Post Budget 2026 Coverages

The coverages include post–Union Budget 2026–27 reactions highlighting key healthcare announcements, featuring a statement by Mr. D. S. Negi,CEO, RGCIRC, emphasising that the exemption of excise/customs duty on 17 cancer drugs will provide timely financial relief to cancer patients and improve the affordability of treatment. He further noted that the ₹10,000 crore investment under the Biopharma Shakti Scheme over the next five years will accelerate innovation in biologics and targeted therapies, strengthening the future of oncology care in India. Overall, the statement highlights the Budget’s role in reinforcing India’s commitment to affordable, advanced, and research-driven cancer care.

Read More